Health & Biotech Prescient Therapeutics hopes to accelerate bid for US FDA study approval for targeted therapy PTX-100 March 21, 2023 Special Report: Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results from its latest… ASX Health Stocks: Healius gets takeover offer from company less than half its size March 20, 2023 Healius (ASX:HLS) has confirmed the receipt of an off-market takeover bid from Australian Clinical Labs (ASX:ACL). ScoPo’s Powerplays: ASX health stocks drop as Neuren surges 60% on US FDA approval March 17, 2023 ASX health stocks have fallen this week in line with broader markets, however Neuren Pharmaceuticals has soared 60% after FDA… ASX Health Stocks: Neurotech says NTI164 works well in 11 autistic children after 52 weeks of treatment March 17, 2023 Neurotech (ASX:NTI) announced clinical results from its 11 paediatric Autism Spectrum Disorder (ASD) patients. Incannex to open psychedelic clinic’s business with leading Australian experts March 17, 2023 Special Report: IHL is undergoing a pivotal point in its journey as a company moving from pure research to service… ASX Health Stocks: High fives as Telix gets expanded FDA approval, Prescient’s PTX-100 returns good results March 16, 2023 Telix Pharma (ASX:TLX) announced the US FDA has approved a supplementary New Drug Application (sNDA) for Illuccix. Incannex’s interim data predicts a statistically significant benefit for psilocybin therapy over placebo when treating anxiety, FDA IND application now in sight March 16, 2023 Special Report: Even though specific data from the PsiGAD trial cannot yet be released until the trial is completed, positive… Wellnex Life joins forces with Chemist Warehouse to enter SAS-B medicinal cannabis market March 14, 2023 Special Report: Wellnex Life will launch five new medicinal cannabis products with leading pharmacy retailer Chemist Warehouse as it looks… ASX Health Stocks: Patrys’ drug exhibits cancer lethality, US Patent Office says yes to Alterity March 14, 2023 Patrys (ASX:PAB) said pre-clinical data of full size IgG deoxymab PAT-DX3 supports the drug’s synthetic lethality mechanism. Could immunotherapy replace chemo? Here’s one stock that could rise 5x according to broker March 14, 2023 Immutep (ASX:IMM) is one company on the ASX which owns one of the most unique immuno-oncology programs out there. Next» « Previous